GIPC1

Across TCGA pan-cancer cohorts, GIPC1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of GIPC1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where GIPC1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GIPC1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, BLCA, and KIRC are the cancer types where GIPC1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GIPC1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.559	<.001	9	view →
BLCA	Male	All	+1.157	<.001	8	view →
KIRC	Male	II,III,IV	−0.636	<.001	8	view →
THCA	Female	II,III,IV	+0.613	<.001	8	view →
UCEC	All	All	+0.928	<.001	6	view →
BRCA	Female	All	+0.695	<.001	6	view →
KICH	All	All	−0.668	<.001	6	view →
LUSC	All	II,III,IV	+0.556	<.001	6	view →
CHOL	Female	All	+2.983	<.001	5	view →
KIRP	All	II,III,IV	+0.575	.003	4	view →
COAD	Male	All	−0.546	.001	4	view →
READ	All	All	−0.816	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

GIPC1–LIHC

Open the LIHC breakdown →